Gregers J. Gram

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01

Anders Fomsgaard, Ingrid Karlsson, Gregers J. Gram et al. · Vaccine · 2011 · 69 citations

Vaccination, Vaccine Target, Human Retrovirus +8

Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4

Gregers J. Gram, A. Hemming, Anders Bolmstedt et al. · Archives of Virology · 1994 · 49 citations

Hiv-1 Gp120, Human Retrovirus, Immunology +11

A Novel Liposome-Based Adjuvant CAF01 for Induction of CD8+ Cytotoxic T-Lymphocytes (CTL) to HIV-1 Minimal CTL Peptides in HLA-A*0201 Transgenic Mice

Gregers J. Gram, Ingrid Karlsson, Else Marie Agger et al. · PLoS ONE · 2009 · 46 citations · Full text

Sensitivity of HIV-1 to neutralization by antibodies against O-linked carbohydrate epitopes despite deletion of O-glycosylation signals in the V3 loop

Jan Erik Hansen, Bengt Jansson, Gregers J. Gram et al. · Archives of Virology · 1996 · 36 citations

O-glycosylation Signals, Biochemistry, Human Retrovirus +12

Gene therapy of T helper cells in HIV infection: Mathematical model of the criteria for clinical effect

Ole Lund, Ole Lund, Gregers J. Gram et al. · Bulletin of Mathematical Biology · 1997 · 28 citations

T Helper Cells, Medicine, Human Retrovirus +11